Overview

Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Clinical Study

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-06-01

Target enrollment:

Participant gender:

Summary

The objective of this clinical trial is to determine whether the addition of immunotherapy combined with chemotherapy before chemoradiotherapy can increase the survival rate of patients with esophageal cancer. It will also assess the safety of this regimen. The primary questions it aims to answer include: * Can the addition of immunotherapy combined with chemotherapy before chemoradiotherapy reduce the rate of disease recurrence among participants? * What adverse reactions will participants experience during the treatment process? * Compared with traditional chemoradiotherapy, will this regimen extend the survival period of participants? Participants will: * Undergo two cycles of immunotherapy combined with chemotherapy, administered every three weeks, followed by concurrent chemoradiotherapy, which includes 28 sessions of radiotherapy and five sessions of chemotherapy during the concurrent period; or proceed directly to concurrent chemoradiotherapy, and then receive two cycles of chemotherapy after the completion of radiotherapy, administered once a month. * Undergo regular tests and examinations to evaluate efficacy and safety. * Record symptoms that occur during the treatment period.

Phase:

PHASE3

Details

Lead Sponsor:

Jiangsu Cancer Institute & Hospital

Collaborator:

Beijing Bethune Charitable Foundation

Treatments:

Carboplatin
Drug Therapy
sintilimab